AstraZeneca champions early kidney disease diagnosis with modelling data
AstraZeneca has highlighted both the economic and environmental benefits of implementing early, targeted screening for chronic kidney disease (CKD). CKD…
AstraZeneca has highlighted both the economic and environmental benefits of implementing early, targeted screening for chronic kidney disease (CKD). CKD…
Johnson & Johnson (J&J) has announced positive topline results for nipocalimab in two rare disease indications - generalised myasthenia gravis…